RLYB Research and Charts

RLYB - Rallybio Corp (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-01-06)

Last 1.03	Change ⇑ +0.02 (+1.98%)	Volume 105,366
	Open 1.01	High 1.08	Low 1.00

8EMA (Daily) 0.98	40EMA (Daily) 1.02	50EMA (Daily) 1.03	STO (Daily) 43.412	MACD Hist (Daily) 0.014
8EMA (Weekly) 1.017	40EMA (Weekly) 1.43	50EMA (Weekly) 1.67	STO (Weekly) 31.756	MACD Hist (Weekly) 0.073


Company Profile
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.